WO2011105556A1 - 筋原性疾患検出用マーカー及びそれを用いた検出方法 - Google Patents
筋原性疾患検出用マーカー及びそれを用いた検出方法 Download PDFInfo
- Publication number
- WO2011105556A1 WO2011105556A1 PCT/JP2011/054318 JP2011054318W WO2011105556A1 WO 2011105556 A1 WO2011105556 A1 WO 2011105556A1 JP 2011054318 W JP2011054318 W JP 2011054318W WO 2011105556 A1 WO2011105556 A1 WO 2011105556A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mir
- mirna
- blood
- subject
- myogenic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 105
- 201000010099 disease Diseases 0.000 title claims abstract description 79
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 79
- 230000001114 myogenic effect Effects 0.000 title claims abstract description 71
- 238000001514 detection method Methods 0.000 title claims description 48
- 239000003550 marker Substances 0.000 title claims description 41
- 210000004369 blood Anatomy 0.000 claims abstract description 64
- 239000008280 blood Substances 0.000 claims abstract description 64
- 239000002679 microRNA Substances 0.000 claims abstract description 36
- 108091070501 miRNA Proteins 0.000 claims abstract description 28
- 201000006938 muscular dystrophy Diseases 0.000 claims description 36
- 230000036765 blood level Effects 0.000 claims description 31
- 238000003753 real-time PCR Methods 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 18
- 238000009396 hybridization Methods 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 108091028606 miR-1 stem-loop Proteins 0.000 abstract description 28
- 108091079012 miR-133a Proteins 0.000 abstract description 24
- 108091024038 miR-133a stem-loop Proteins 0.000 abstract description 24
- 108091063796 miR-206 stem-loop Proteins 0.000 abstract description 24
- 108091079016 miR-133b Proteins 0.000 abstract description 8
- 108091043162 miR-133b stem-loop Proteins 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 108700011259 MicroRNAs Proteins 0.000 description 76
- 210000002966 serum Anatomy 0.000 description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 27
- 102000004420 Creatine Kinase Human genes 0.000 description 25
- 108010042126 Creatine kinase Proteins 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 239000000523 sample Substances 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 238000012937 correction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 108091027943 miR-16 stem-loop Proteins 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 238000011002 quantification Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002123 RNA extraction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 4
- 210000001766 X chromosome Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 108091023685 miR-133 stem-loop Proteins 0.000 description 4
- 238000003380 quartz crystal microbalance Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 3
- 108010069091 Dystrophin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000003253 miRNA assay Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 108091007428 primary miRNA Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028080 MiR-132 Proteins 0.000 description 2
- 208000034819 Mobility Limitation Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002156 adsorbate Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028629 Myoglobinuria Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- -1 phosphorothioate DNA Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000013545 self-assembled monolayer Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the present invention relates to a myogenic disease detection marker and a method for detecting the presence or absence of a myogenic disease, particularly a muscular dystrophy, using the same.
- Muscular dystrophy a type of myogenic disease, is a progressive genetic disease that causes muscle atrophy and muscle weakness due to degeneration or necrosis of muscle fibers of skeletal muscle.
- Various types of disease such as Duchamp type, Becker type, limb band type, face-scapular upper arm type, etc. are known depending on the genetic form and clinical symptoms (Non-patent Document 1).
- Diagnosis of muscular dystrophy is performed by comprehensively including clinical symptoms, blood tests, examination findings, electromyography, muscle biopsy, genetic testing, and the like.
- the blood test is performed by measuring the amount of an enzyme such as creatine kinase, lactate dehydrogenase, glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), or aldolase.
- an enzyme such as creatine kinase, lactate dehydrogenase, glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), or aldolase.
- the blood test method is based on the phenomenon that these enzymes, which are contained in a large amount of muscle cells, leak into the blood due to necrosis of muscle cells and become higher than normal in muscular dystrophy patients. Since detection with peripheral blood is possible, the invasiveness to a subject is low and the measurement method is relatively simple. Therefore, it is widely used in the diagnosis of muscular dystrophy.
- a method for measuring the creatine kinase level in serum is common (Non-patent Document 2).
- the concentration in serum greatly varies depending on whether or not the subject has exercise load. Therefore, even a healthy person has a high value of creatine kinase, etc., and there is a problem that the subject before blood collection must be put in a resting state for the problem of misjudgment or accurate judgment.
- An object of the present invention is to provide a marker for detecting a myogenic disease that has low invasiveness to a subject and has high stability to exercise load, and a method for detecting myogenic disease, particularly a muscular dystrophy, using the same. It is.
- miRNA microRNAs
- miR-1 miR-1
- miR-133 two mutants miR-133a
- miR-206 blood levels of miR-133b (including miR-133b) and miR-206 are closely related to myogenic disease, particularly muscular dystrophy, and are hardly affected by exercise.
- miR-1 and miR-133 are specifically expressed in cardiac muscle, atrium and skeletal muscle, and that miR-206 is specifically expressed in skeletal muscle (Kim et al. , 2006, J.
- nucleic acid amplification method is a real-time PCR method.
- a myogenic disease detection marker comprising a miRNA comprising the nucleotide sequence represented by SEQ ID NOs: 1 to 4.
- the myogenic disease detection marker of the present invention it is possible to provide a disease detection marker for a myogenic disease that is not affected by the exercise load of the subject.
- the presence or absence of the myogenic disease in the subject is low without being affected by the subject's exercise load with low invasiveness.
- a method that can be detected can be provided.
- the relative value of the serum level of each miRNA of mdx mice with respect to B10 mice is shown. It is the figure which showed the change of the miR-1, miR-133a, and miR-206 amount in serum in the elapsed time after the exercise load of a B10 mouse
- a is miR-1
- b is miR-133a
- c is miR-206
- d is creatine kinase (CK)
- white circle / dashed line is B10 mouse
- black circle / solid line is mdx mouse Respectively.
- a is miR-1
- b is miR-133a
- c is miR-206
- d is creatine kinase (CK)
- white circle / dashed line is B10 mouse
- black circle / solid line is mdx mouse Respectively.
- the change in serum after birth such as miRNA in a muscular dystrophy model dog CXMDj or its carrier dog is shown.
- the amount of miRNA or the like is indicated by the relative value of the correction value at the corresponding time of the corresponding miRNA or the like in a healthy dog after correction with the amount of miRNA16 in serum.
- the 1st aspect of this invention is a marker for a myogenic disease detection. By measuring the amount of a specific miRNA that is a myogenic disease detection marker of the present embodiment in blood, it is possible to detect the presence or absence of myogenic disease, particularly muscular dystrophy.
- the myogenic disease detection marker of the present invention is composed of miRNA containing the base sequences shown in SEQ ID NOs: 1 to 4.
- the “marker for detecting a myogenic disease” is an index for detecting the presence or absence of a myogenic disease in a test individual.
- the marker specifically for skeletal muscle and myocardium is used.
- Specific miRNAs to be expressed that is, miR-1, miR-133 (miR-133a and miR-133b) and miR-206, which are specifically described below.
- the myogenic disease detection marker includes any one of the miRNAs or a combination of two or more thereof.
- myogenic disease refers to a disease in which muscles atrophy and muscle weakness occurs.
- muscular dystrophy including Dushan type, Becker type, Emery Dreyfus type, limb girdle type, facial scapulohumeral type, ophthalopharyngeal type, congenital muscular dystrophy
- myopathy congenital, distal type, hypothyroidism Sex, including steroid myopathy
- inflammatory myopathy including polyarthritis, cutaneous arthritis
- Danone disease myasthenia syndrome
- mitochondrial disease myoglobinuria, glycogenosis, periodic limb paralysis, etc. included.
- the preferred myogenic disease is muscular dystrophy.
- MiRNA is a single-stranded non-coding RNA having a length of 21 to 23 bases existing in a cell. This small RNA binds to the target gene mRNA and protein factors to form a complex, and inhibits target gene translation by the action of RISC (RNA-induced silencing complex) / miRNP. It is known to regulate expression. miRNA is transcribed from the genome in a precursor (pre-precursor) state called pri-miRNA, then processed into a precursor called pre-miRNA in the nucleus by an endonuclease called Drosha, and then dicer outside the nucleus.
- precursor pre-precursor
- Drosha endonuclease
- the miRNA of the present invention includes both miRNA precursors and mature miRNAs. Preferably, it is a mature miRNA. This is because mature miRNAs can directly contribute to the regulation of target gene expression.
- the nucleotide sequence shown in SEQ ID NO: 1 is human mature miR-1
- the nucleotide sequence shown in SEQ ID NO: 2 is human mature miR-133a
- the nucleotide sequence shown in SEQ ID NO: 3 is human mature miR-133b
- the base sequence represented by SEQ ID NO: 4 corresponds to human mature miR-206, respectively.
- these nucleotide sequences are completely conserved in many mammals such as mice, rats, and dogs, these miRNAs are not only used in humans but also in other mature species having the same nucleotide sequence. May also apply.
- miR-1 and miR-133 are known to be specifically expressed in cardiac muscle, atrium and skeletal muscle, and miR-206 is known to be specifically expressed in skeletal muscle (KimKet al., 2006). , J. Cell Biochem, 174, 677-687).
- the miRNA of the present invention includes both precursors (pri-miRNA, pre-miRNA) and matured bodies. Therefore, the myogenic disease detection marker of the present invention also includes a precursor of each miRNA containing the base sequence represented by SEQ ID NOs: 1 to 4 as a part thereof. As the myogenic disease detection marker of the present invention, various mature miRNAs comprising the nucleotide sequences represented by SEQ ID NOs: 1 to 4 are more preferable.
- the myogenic disease detection marker of the present invention can be used as a detection marker for a myogenic disease detection method in the second aspect of the present invention described later.
- the 2nd aspect of this invention is a method of detecting the presence or absence of the myogenic disease in a test subject, especially the muscular dystrophy. This method measures the amount of one or more specific miRNAs present in the blood of a subject, that is, the amount of the myogenic disease detection marker of the first aspect, thereby causing the subject to suffer from a myogenic disease. It is characterized by detecting whether or not.
- the detection method of the present invention includes a measurement step and a comparison step. Hereinafter, each step will be specifically described.
- Measurement step refers to the marker for detecting a myogenic disease of the first aspect, which is present in blood collected from a subject, that is, an miRNA comprising the base sequence represented by SEQ ID NOs: 1 to 4 It is a step of measuring any one or more amounts.
- subject refers to an individual subjected to a test for the presence or absence of a myogenic disease.
- the subject organism is a mammal, preferably a human.
- blood includes whole blood, plasma and serum. Any of venous blood, arterial blood, bone marrow fluid or umbilical cord blood may be used.
- blood collected from a subject refers to blood collected directly from a subject or indirectly collected blood. Such blood includes those collected from subjects placed in a resting state before collection and those collected from subjects after exercise.
- the term “resting state” refers to a state in which the subject is placed in a lying or sitting position and skeletal muscle movement is stopped as much as possible.
- it is an animal other than a human, it means a peaceful living state that does not give excessive exercise or stress.
- “exercise load” means that a positive load is applied to the skeletal muscle regardless of the posture of the subject. For example, walking, running, elevating / lowering stairs, etc. or sports are applicable.
- the directly collected blood includes, for example, those obtained by directly inserting a needle into a subject such as peripheral blood and bone marrow fluid, and those obtained directly from the umbilical cord after delivery such as umbilical cord blood. It is. In the case of collecting directly from a subject, it may be collected from blood according to a known method. For example, peripheral blood was collected by injection into peripheral veins, etc., umbilical cord blood was collected by inserting a needle into the umbilical cord before delivery of the postpartum placenta, and bone marrow fluid. Any of those collected by bone marrow puncture (Marc) may be used. Peripheral blood collected by injection is more preferable because it is less invasive to the subject and can be easily obtained without selecting the time of collection.
- Indirectly collected blood is obtained by adding heparin or the like to the directly collected whole blood and applying anticoagulation treatment, or separating it as plasma or serum, and then storing it in a refrigerated or frozen state. Includes re-collected materials.
- the “blood collected from a subject” may be any subject with or without exercise load before blood collection. Creatine kinase, which has been used in the examination of muscular dystrophy, which is a typical myogenic disease, varies greatly in blood levels before and after exercise, so it is necessary to keep the subject in a resting state before collecting blood. there were.
- Creatine kinase which has been used in the examination of muscular dystrophy, which is a typical myogenic disease, varies greatly in blood levels before and after exercise, so it is necessary to keep the subject in a resting state before collecting blood. there were.
- Example 1 described later since the blood concentration of the myogenic disease detection marker of the first aspect is stable before and after exercise load, Even blood collected from a subject (immediately to 24 hours) can be used.
- the volume of blood used in the method of the present invention is usually 50 ⁇ L or more, preferably 100 ⁇ L or more, and 500 ⁇ L or less, preferably 1 mL or less.
- Whole blood collected from the subject is treated so that the blood does not clot.
- a method of pre-coating the inside of a syringe used for blood collection with a blood coagulation inhibitor such as heparin, or a blood coagulation inhibitor, or a treatment method of adding a blood coagulation inhibitor to the collected whole blood (in this case, if heparin is added, the final concentration may be 10 to 100 units / mL.)
- Whole blood treated with the anticoagulant or the like is centrifuged at an appropriate speed, and the supernatant is prepared as plasma.
- a method in which the whole blood is allowed to stand at room temperature and then centrifuged at an appropriate speed to prepare the supernatant as serum.
- the “amount” of the present invention is a term representing the amount of a myogenic disease detection marker in blood.
- a relative amount such as a concentration or the absolute amount of miRNA contained in a given volume of blood.
- a relative amount or an absolute amount may be used.
- a relative amount is preferred.
- the method for measuring the amount of the marker for detecting myogenic disease of the first aspect present in blood is not particularly limited as long as it can detect and quantify the amount of the marker.
- examples thereof include a nucleic acid amplification method, a hybridization method, and an RNase protection method.
- Nucleic acid amplification method refers to a method of amplifying a specific region of a target nucleic acid with a nucleic acid polymerase using a forward / reverse primer set.
- PCR method including RT-PCR method
- NASBA method NASBA method
- ICAN method ICAN method
- LAMP (registered trademark) method including RT-LAMP method
- the PCR method is preferred. This is because the PCR method is the most widely used method in the field, and reagents, kits, reaction devices, and the like are available, and various applied technologies have been developed.
- a nucleic acid amplification method via reverse transcription reaction for example, RT-PCR method or RT-LAMP method is usually employed.
- RT reaction reverse transcription reaction
- a quantitative PCR method such as a real-time PCR method is used. Is preferably used.
- Real-time PCR is a reaction system in which PCR products are specifically fluorescently labeled in the gene amplification reaction process, and is analyzed by performing PCR using a temperature cycler device equipped with a device for detecting fluorescence intensity.
- a method for labeling a PCR product examples include a method using a fluorescently labeled probe such as TaqMan (registered trademark) PCR method and a method using a reagent that specifically binds to double-stranded DNA.
- the TaqMan PCR method uses a probe modified with a quencher substance at the 5 'end and a fluorescent dye at the 3' end.
- the quencher substance at the 5 ′ end part suppresses the fluorescent dye at the 3 ′ end part, but when PCR is performed, the probe is degraded by the 5 ′ ⁇ 3 ′ exonuclease activity of Taq polymerase, As a result, quenching of the quencher substance is released, and fluorescence is emitted.
- the amount of fluorescence reflects the amount of PCR product. Since the number of cycles (CT) when the PCR product reaches the detection limit and the initial template amount are inversely correlated, the real-time measurement method quantifies the initial template amount by measuring CT.
- the absolute value of the initial template amount of the unknown sample can be calculated by measuring the CT using a known amount of the template in several stages and preparing a calibration curve.
- the amplification product can be detected and quantified in combination with the hybridization method described below.
- hybridization method is a method in which a nucleic acid fragment having a base sequence complementary to all or part of the base sequence of a target nucleic acid to be detected is used as a probe, and base pairing between the nucleic acid and the probe is used. This is a method for detecting and quantifying a target nucleic acid or a fragment thereof.
- Several methods with different detection means are known as hybridization methods.
- the target nucleic acid is miRNA, for example, Northern hybridization method (Northern blot hybridization method), RNA microarray method The surface plasmon resonance method or the quartz crystal microbalance method is preferable.
- RNA prepared from a sample is separated by electrophoresis on agarose gel or polyacrylamide gel under denaturing conditions, and transferred to a filter (blotting). ), And then detecting the RNA using a probe having a base sequence specific to the target RNA.
- an appropriate marker such as a fluorescent dye or a radioisotope, for example, a chemirumi (chemiluminescence) imaging analyzer (for example, Light Capture; Ato), a scintillation counter, an imaging analyzer (for example, FUJIFILM) :
- the target RNA can also be quantified using a measuring device such as BAS series.
- RNA microarray method is a method in which DNA microarray method is applied to RNA.
- a nucleic acid fragment complementary to all or part of the base sequence of a target nucleic acid on a substrate is placed as a probe in a high density in a small spot and solid-phased.
- This is a method for detecting and quantifying a nucleic acid hybridized to a spot by fluorescence or the like. Detection and quantification can be achieved by detecting and measuring fluorescence based on hybridization of a target nucleic acid or the like with a microplate reader or a scanner.
- the RNA microarray method is also a well-known technique in the art. For example, see DNA microarray method (DNA microarray and latest PCR method (2000) Masaaki Muramatsu, supervised by Hiroyuki Nami, Shujunsha).
- SPR surface plasmon resonance
- the target miRNA can be detected and quantified from the difference in the measured values before and after the sample flow by forming a base pairing between the target miRNA and the nucleic acid probe by circulating blood on the surface of the metal thin film.
- Detection and quantification by the surface plasmon resonance method can be performed using, for example, an SPR sensor commercially available from Biacore. This technique is well known in the art. See, for example, Kazuhiro Nagata and Hiroshi Handa, real-time analysis experiment of biological material interactions, Springer Fairlake Tokyo, Tokyo, and 2000.
- the “Quartz Crystal Microbalance (QCM) method” uses the phenomenon that when a substance is adsorbed on the surface of an electrode attached to a crystal resonator, the resonance frequency of the crystal resonator decreases according to its mass. Thus, this is a mass measurement method that quantitatively captures a very small amount of adsorbate based on the amount of change in resonance frequency.
- the detection and quantification by this method were also collected from a subject using a commercially available QCM sensor as in the SPR method, for example, a nucleic acid probe having a sequence complementary to the base sequence of the target miRNA immobilized on the electrode surface.
- Target miRNA can be detected and quantified by base pairing with target miRNA in blood. This technique is well known in the art, for example, J.
- the probe used in the hybridization method may be a nucleic acid fragment having a base sequence complementary to all or part of the base sequence represented by SEQ ID NOs: 1 to 4.
- the base length of the probe is 8 bases or more, preferably 10 bases or more, more preferably 12 bases or more, still more preferably 15 bases or more, or less than the full length.
- the nucleic acid constituting the probe may be usually DNA, RNA or a combination thereof, but if necessary, all or part of the PNA (Peptide Nucleic Acid), LNA (Locked Nucleic Acid; registered trademark), methylphosphonate DNA Chemically modified nucleic acids such as phosphorothioate DNA, 2′-O-methyl RNA, pseudo-nucleic acids, or combinations thereof may also be included.
- Probes used in the hybridization method include fluorescent dyes (for example, fluoresamine and derivatives thereof, rhodamine and derivatives thereof, FITC, cy3, cy5, FAM, HEX, VIC), quencher substances (TAMRA, DABCYL, BHQ-1, Modification or labeling with BHQ-2 or BHQ-3), biotin or (strept) avidin, modifying substances such as magnetic beads, or radioisotopes (eg, 32 P, 33 P, 35 S) Can do.
- Hybridization is preferably performed under stringent conditions. This is to eliminate non-target nucleic acids that hybridize non-specifically.
- RNA protection method is a method in which a target RNA and probe are hybridized using a probe having a base sequence complementary to the target RNA, and then the hybridized RNA that is free from degradation by RNase treatment is electrophoresed.
- the target RNA is detected and quantified by separating and detecting the target RNA.
- the method of separation and detection by electrophoresis is basically the same as the hybridization method.
- Comparison process means that the blood level of the miRNA in a subject is statistically significantly higher than the blood level of the corresponding miRNA in a healthy individual, and the subject has a myogenic disease It is the process of associating having suffered from. This association determines whether the subject has a myogenic disease. That is, when the blood level of any one or more of a particular miRNA in a subject is statistically significantly higher than the blood level of the corresponding miRNA in a healthy individual, the subject is It is determined that the person is affected by the disease or is likely to develop in the near future.
- the blood level of the miRNA refers to the amount in the blood of any one or more of the miRNAs containing a nucleotide sequence shown in SEQ ID NOs: 1 to 4, ie, a marker for detecting a myogenic disease.
- the term “healthy individual” refers to an individual that is the same species as a subject and at least apparently does not suffer from a myogenic disease, preferably a healthy individual that does not suffer from any disease.
- the miRNA corresponding to the healthy individual refers to the same miRNA as the miRNA of the subject measured in the measurement step. For example, when miR-1 of a subject is a measurement target in the measurement step, the corresponding miRNA is miR-1 of a healthy individual.
- the blood level of miRNA of a healthy individual used in this step can be used in the measurement step of the present invention, in addition to the measurement of the blood level of miRNA in the subject and the corresponding blood level of miRNA measured,
- the blood level of the corresponding miRNA measured in advance under the same conditions as the measurement of the blood level of the subject's miRNA can also be used.
- the blood level of each miRNA that is a marker for detecting a myogenic disease in a healthy individual is created as a database, the measurement of the blood level of the marker for detecting a myogenic disease in a subject can be measured. This is convenient because there is no need to measure in parallel each time.
- Statistically significant means that when a quantitative difference between the two corresponding miRNAs in the blood is statistically processed, there is a significant difference between the two. Specifically, for example, the risk rate (significance level) is less than 5%, 1%, or 0.1%.
- the test method for statistical processing is not particularly limited as long as a known test method capable of determining the presence or absence of significance is appropriately used. For example, Student's t test or multiple comparison test can be used.
- “statistically significantly high” means, for example, that the blood level of a marker for detecting a myogenic disease in a subject is the blood level of the marker for detecting a myogenic disease corresponding to a healthy individual 5 times or more, preferably 10 times or more.
- the blood concentration of miR-1 in a subject may be 5 or more in relative value relative to the blood concentration of miR-1 in a healthy individual.
- “Associating” in the present invention means that the comparison result of the blood level of miRNA, which is a marker for detecting myogenic diseases, is linked to the morbidity or onset potential of myogenic diseases.
- the blood level of a marker for detecting myogenic disease was statistically determined between an individual suffering from a myogenic disease or having a possibility of developing in the near future and a healthy individual. It was found that there was a significant quantitative difference. Based on this finding, in the present invention, if the blood level of the myogenic disease detection marker in the subject is statistically significantly higher than the blood level of the miRNA corresponding to the healthy individual, It is determined that the subject has a myogenic disease or is likely to develop in the future.
- RNA extraction from blood When the collected blood is whole blood, it can be prepared into serum or plasma. When preparing serum, leave whole blood at room temperature for 20 minutes to 1 hour, then ice-cool and centrifuge at 2500 rpm to 4000 rpm for 10 minutes to 20 minutes at 4 ° C to obtain the supernatant. Good. When preparing plasma, whole blood may be centrifuged at 5000 ⁇ g for 15 minutes at 4 ° C., for example.
- RNA extraction methods known in the art may be used. For example, extraction can be performed according to the RNA extraction method described in Sambrook, J. et. Al., (1989) Molecular Cloning: a Laboratory Manual Second Ed., Cold SpringHarbor Laboratory Press, Cold Spring Harbor, New York. RNA may be prepared as total RNA (Total RNA).
- a commercially available RNA extraction kit from each manufacturer can also be used. Some of these commercially available RNA extraction kits have been developed for the purpose of efficiently recovering microRNA present in a sample so that only small RNA can be selectively extracted.
- the invention can also be suitably used. Specifically, for example, mirVana microRNA isolation kit (Ambion) can be mentioned. When using a kit, the specific method may be performed according to or according to the protocol attached to the kit.
- the nucleic acid to be detected in the present invention is a miRNA whose mature body is only about 20 bases long. Therefore, a quantitative nucleic acid amplification method via a general RT reaction, for example, a real-time RT-PCR method, cannot be appropriately amplified because the target nucleic acid is too short. Therefore, when detecting a myogenic disease detection marker in blood using a nucleic acid amplification method, for example, amplification may be performed using a kit or a special primer commercially available from the manufacturer. An example is the Applied Biosystems TaqMan MicroRNA Assays Kit commercially available from Life Technologies.
- each miRNA-specific Looped RT primer included in this kit is useful because it allows efficient amplification after reverse transcription of the target mature miRNA.
- the Looped RT primer self-forms a hairpin structure in which the 3 ′ terminal part protrudes several bases having a sequence complementary to the 3 ′ terminal region of the target mature miRNA. After the protruding 3 ′ end portion anneals with the 3 ′ end region of the target miRNA, it is extended with RTase using the target miRNA as a template. Thereafter, by performing normal real-time PCR using the extension product as a template, the target miRNA can be specifically amplified.
- the reaction conditions for real-time PCR are generally based on known PCR methods, the base length of the nucleic acid fragment to be amplified and the amount of template nucleic acid, the base length and Tm value of the primer to be used, and the optimal reaction of the nucleic acid polymerase to be used. Since it fluctuates depending on temperature, optimum pH, etc., it may be determined appropriately according to these conditions. For example, a denaturation reaction is usually performed at 94 to 95 ° C. for 5 seconds to 5 minutes, an annealing reaction is performed at 50 to 70 ° C. for 10 seconds to 1 minute, and an extension reaction is performed at 68 to 72 ° C. for 30 seconds to 3 minutes. One cycle can be repeated for about 15 to 40 cycles, and finally an extension reaction can be performed at 68 to 72 ° C. for 30 seconds to 10 minutes. When using a kit commercially available from the manufacturer, the protocol attached to the kit may be used in principle.
- the nucleic acid polymerase used in real-time PCR is a DNA polymerase, particularly a heat resistant DNA polymerase.
- Various types of such nucleic acid polymerases are commercially available, and they can also be used.
- Taq DNA polymerase attached to Applied Biosystems TaqMan MicroRNA Assays Kit can be mentioned.
- such a commercially available kit is useful because a buffer optimized for the activity of the attached DNA polymerase is attached.
- the presence or absence of a myogenic disease in a subject can be detected with high sensitivity without being affected by the exercise load of the subject. Can do.
- the conventional method for detecting myogenic diseases with blood creatine kinase level fluctuations due to exercise load were large, so in order to make an accurate diagnosis, the subject should be tested before collecting a sample for detection such as blood. Needed to be kept at rest. However, this forced the subject to exercise excessively, and the burden on the subject was not small. Therefore, with the detection method of this aspect, the burden on the subject before blood collection can be greatly reduced.
- the method for detecting the presence or absence of a myogenic disease of this aspect since it can be detected in peripheral blood, the invasiveness given to the subject in sampling is low.
- Example 1 ⁇ Verification of muscular dystrophy detection marker using muscular dystrophy model mouse> The effect of the muscular dystrophy detection marker of the present invention and the muscular dystrophy detection method using the same was verified using a muscular dystrophy model mouse.
- mdx mice male individual; 8 weeks old
- Dushan muscular dystrophy is caused by a deficiency in the dystrophin gene due to recessive inheritance of the X chromosome linkage.
- B10 mice male individuals; 8 weeks old
- the mdx mouse has the same genetic background as the B10 mouse except for the dystrophin gene deficiency.
- mice Blood collection and serum preparation
- 100 ⁇ L or more of blood was collected from the tail artery using a 29G needle and a 0.5 mL syringe. Then, in order to give an exercise load, each mouse was run for 15 minutes by accelerating at 5 m / min for 5 minutes using a treadmill (running machine) and then at 1 m / min every minute thereafter.
- a treadmill running machine
- blood was collected in the same manner as described above after 6 hours and 48 hours.
- the collected whole blood was allowed to stand at room temperature for 30 minutes or more, and then centrifuged at 3000 rpm for 10 minutes using a centrifuge (KUBOTA 2410) to obtain a supernatant as serum.
- KUBOTA 2410 a centrifuge
- each mature miRNA contained in the eluate (mi-R1: SEQ ID NO: 1, mi-R16, mi-R132, mi-R133a: SEQ ID NO: 2, mi-R133b: SEQ ID NO: 3, mi-R206: SEQ ID NO: 4) and mature sno202 (SEQ ID NO: 5), which is one of small nuclear RNAs (snoRNA), were quantified by real-time PCR.
- snoRNA small nuclear RNAs
- RNA amount in each sample of this example was used as an endogenous control.
- miR-132 is known to express specifically in nerve cells, it was used as a negative control in this example.
- sno202 is an RNA generally used as an endogenous control in the quantification of mouse miRNA.
- the protocol attached to the kit was followed. Specifically, it is as follows.
- reaction reagents include 100 mM dNTPs; 0.15 ⁇ L / RTase (Superscript); 1.0 ⁇ L / 10 ⁇ RT buffer; 1.5 ⁇ L / RNasin; 0.188 ⁇ L / 5 ⁇ the primer; 3.0 ⁇ L / total RNA (2 ⁇ g / ⁇ L); A total reaction volume of 15.0 ⁇ L consisting of 5.0 ⁇ L was used.
- the reaction conditions for the reverse transcription reaction were as follows: annealing reaction at 16 ° C. for 30 minutes, reverse transcription reaction at 42 ° C. for 30 minutes, and RTase inactivation at 85 ° C. for 5 minutes. Placed at 4 ° C.
- miR-133a which is a mutant of miR-133a, has almost the same behavior and function, miR-133a is shown in the following examples.
- FIG. This figure shows B10 mice (open circles; dashed lines) and mdx mice (filled circles; miR-1 (a), miR-133a (b), miR-206 (c) and creatine kinase (CK) (d) in serum.
- the relative values in (solid line) are shown. From this figure, it was found that the amounts of miR-1, miR-133a and miR-206 in serum were higher in mdx mice than in B10 mice.
- miR-1, miR-133a, and miR-206 had the same tendency to change immediately after exercise, but the amount of change, that is, the fluctuation range, was very small compared to creatine kinase.
- the maximum value after exercise with respect to before exercise is 70 times or more for creatine kinase, but only 10 times or less for miR-1, miR-133a and miR-206. Therefore, it was confirmed that these miRNAs can serve as markers for detecting muscular dystrophy even after exercise.
- Example 2 ⁇ Verification of muscular dystrophy detection marker using muscular dystrophy model dog> The effect of the muscular dystrophy detection marker of the present invention and the detection method using the same was verified using a muscular dystrophy model dog. Unlike muscular dystrophy patients, mdx mice do not exhibit symptoms such as difficulty walking, but muscular dystrophy dogs lacking the dystrophin gene due to recessive inheritance of the X chromosome linkage, similar to mdx mice, have similar symptoms to humans such as difficulty walking. Indicates. Therefore, it is possible to verify an effect closer to that of a human.
- a beagle dog of the CXMDJ strain having an abnormality in the dystrophy gene on the X chromosome As a muscular dystrophy model dog, a beagle dog of the CXMDJ strain having an abnormality in the dystrophy gene on the X chromosome, a carrier dog (a female beagle dog having an abnormality in one dystrophy gene of the X chromosome pair) and a healthy dog (abnormal in the dystrophy gene) Not beagle dogs).
- Creatin kinase activity RNA extraction from serum, and quantification of miRNA (miR-1, miR-16, miR-133a, and miR-206) in serum by real-time PCR using the same were as in Example 1.
- FIG. 1 shows the quantitative values of miR-16 for the miR-1, miR-133a, miR-206 and creatine kinase in the serum of CXMDJ strain individuals and carrier dogs by real-time PCR. It correct
- the serum levels of miR-1, miR-133a and miR-206 which are markers for detecting muscular dystrophy of the present invention, all showed almost the same changes as the behavior of creatine kinase. Therefore, it was revealed that these markers are effective even in muscular dystrophy model dogs.
Abstract
Description
1-1.概要
本発明の第1の態様は、筋原性疾患検出用マーカーである。本態様の筋原性疾患検出用マーカーである特定のmiRNAの血液中の量を測定することによって、筋原性疾患罹患、特に筋ジストロフィー罹患の有無を検出することができる。
本発明の筋原性疾患検出用マーカーは、配列番号1~4で示される塩基配列を含むmiRNAによって構成される。
本発明の筋原性疾患検出用マーカーによれば、後述する本発明の第2の態様において筋原性疾患検出方法の検出用マーカーとして使用することができる。
2-1.概要
本発明の第2の態様は、被験体における筋原性疾患、特に筋ジストロフィーの罹患の有無を検出する方法である。本方法は、被験体の血液中に存在する一以上の特定のmiRNA量、すなわち第1態様の筋原性疾患検出用マーカーの量を測定することによって、その被験体が筋原性疾患に罹患しているか否かを検出することを特徴とする。
本発明の検出方法は、測定工程及び比較工程を含む。以下、各工程について具体的に説明をする。
「測定工程」とは、被験体から採取された血液中に存在する前記第1の態様の筋原性疾患検出用マーカー、すなわち、配列番号1~4で示される塩基配列を含むmiRNAのいずれか一以上の量を測定する工程である。
「比較工程」とは、被験体における前記miRNAの血中量が健常個体の対応するmiRNAの血中量と比較して統計学的に有意に高いこととその被験体が筋原性疾患に罹患していることを関連づける工程である。この関連付けによって、被験体が筋原性疾患に罹患しているか否かが判断される。すなわち、被験体における特定のmiRNAにいずれか一以上の血中量が健常個体における対応するmiRNAの血中量と比較して統計学的に有意に高いときには、その被験体は、筋原性疾患に罹患している又は近い将来に発症する可能性が高いと判定される。
<リアルタイムPCR法を用いたmiRNAの血中量の測定>
(1)血液からのRNA抽出
採取された血液が全血の場合は、血清又は血漿に調製することができる。血清を調製する場合には、全血を室温で20分間~1時間程度放置した後、氷冷し、4℃にて2500rpm~4000rpmで10分~20分間遠心して、その上清を得ればよい。また、血漿を調製する場合には、全血を、例えば、4℃にて5000×gで15分間遠心すればよい。
前述のように、本発明で検出すべき核酸は、成熟体が約20塩基長しかないmiRNAである。したがって、一般的なRT反応を介した定量的核酸増幅法、例えば、リアルタイムRT-PCR法では標的核酸が短すぎて適当に増幅することができない。そこで、核酸増幅法を用いて血液中の筋原性疾患検出用マーカーを検出する場合には、例えば、メーカーから市販されているキットや特殊なプライマーを利用して増幅すればよい。一例として、Life Technologies社から市販されているApplied Biosystems TaqMan MicroRNA Assays Kitが挙げられる。このキットに付属の各miRNA特異的なLooped RTプライマーを使用すれば、目的の成熟miRNAを効率的に逆転写させた後に増幅が可能となるため有用である。Looped RTプライマーは、3’末部分が標的成熟miRNAの3’末領域に相補的な配列を有する数塩基突出したヘアピン構造を自己形成する。その突出した3’末部分が標的miRNAの3’末領域とアニーリングした後、RTaseで標的miRNAを鋳型に伸長される。その後、伸長産物を鋳型に通常のリアルタイムPCRを行うことで、標的miRNAを特異的に増幅することが可能となる。
本態様の筋原性疾患の罹患の有無を検出する方法によれば、被験体の運動負荷による影響を受けることなく、被験体における筋原性疾患の罹患の有無を高感度に検出することができる。従来の血中クレアチンキナーゼ値による筋原性疾患罹患の検出方法では、運動負荷による変動が大きかったことから、正確な診断を行なうためには、血液等の検出用試料を採取する前に被験体を安静状態に保つ必要があった。しかし、これは被験体に過度の運動制限を強いることになり、被験体におけるその負担は少なくなかった。それゆえ、本態様の検出方法であれば、採血前の被験体の負担を大きく軽減することができる。
<筋ジストロフィーモデルマウスを用いた筋ジストロフィー検出用マーカーの検証>
本発明の筋ジストロフィー検出用マーカーとそれを用いた筋ジストロフィー検出方法の効果を、筋ジストロフィーモデルマウスを用いて検証した。
筋ジストロフィーのモデルマウスには、デュシャン型筋ジストロフィーの疾患モデルであるmdxマウス(mdx/B10)(雄個体;8週齢)を使用した。デュシャン型筋ジストロフィーは、X染色体連鎖の劣性遺伝によるジストロフィン遺伝子の欠損により発症する。また、コントロール(健常個体)群としてB10マウス(雄個体;8週齢)を使用した。なお、mdxマウスは、ジストロフィン遺伝子の欠損を除けば、B10マウスと遺伝的バックグラウンドが同一である。
採血及び血清の調製
上記各マウスを動物実験施設内に搬入後、移送や環境変化によるストレスを軽減させるため、1週間以上、1匹ずつケージに分けて予備飼育した。各マウスに運動負荷を与える1週間前に29G注射針と0.5mLシリンジを用い、尾動脈から100μL以上採血した。その後、運動負荷を与えるため、トレッドミル(ランニングマシーン)を用いて5m/分を5分、その後1分ごとに1m/分ずつ加速して15分間、各マウスを走らせた。運動負荷終了直後(30分以内;グラフでは0hで示す)、6時間後、48時間後に、上記と同様の方法で採血を行なった。
それぞれの血清から50μLを分注し、生化学分析装置(富士ドライケムシステム)を用いてクレアチンキナーゼ活性を測定した。
・RNA抽出
それぞれのサンプルの残った50μL血清からAmbion mirVana microRNA isolation kitを用いて全RNAを抽出し、最後に50μLの溶出液を用いてカラムからRNAを溶出し、これを全RNA溶液とした。RNAの抽出手順については、添付のプロトコルに従った。
前記全RNA溶液のうち5μLを用いて、当該溶出液中に含まれる各成熟miRNA(mi-R1:配列番号1、mi-R16、mi-R132、mi-R133a:配列番号2、mi-R133b:配列番号3、mi-R206:配列番号4)及び核内低分子RNA(snoRNA)の一つである成熟sno202(配列番号5)をリアルタイムPCRで定量した。増幅反応には、Applied Biosystems TaqMan microRNA assay kit(Life Technologies社)を使用した。
リアルタイムPCRによる定量結果に基づき、運動負荷を与えない、すなわち運動前のmdxマウスの血清中における各種miRNA等の平均量(n=5)について検証した。B10マウスの血清中における各miRNA量又はsnoRNA量を1としたときのmdxマウスの血清中における対応するmiRNA量又はsnoRNA量の相対値で表した。
図1の結果から選択されたmiR-1、miR-133a及びmiR-206の運動負荷による血清中の量の変化について検証した。リアルタイムPCRにより測定した運動前及び運動負荷後の各経過時間における血清中のmiR-1、miR-133a及びmiR-206の量をmiR-16の量にて補正(各miRNAのCt/miR-16 Ctを算出)後、得られた各サンプルの補正値を、それぞれのマーカー候補の運動前のB10マウスにおける補正値(1とする)に対する相対値で表した。
さらに、運動負荷による血清中の量の変化を、miRNA又はクレアチンキナーゼのそれぞれの運動前との相対値で検証した。前記(2)と同様にリアルタイムPCRにより測定したB10及びmdxマウスの運動前における及び運動負荷後の各経過時間における血清中のmiR-1、miR-133a及びmiR-206の量をmiR-16の量にて補正(各miRNAのCt/miR-16 Ctを算出)した後、得られた各サンプルの運動負荷後の補正値をそれぞれの運動前の補正値、すなわち、B10についてはB10の運動前の補正値に、mdxについてはmdxの運動前の測定値に、対する相対値でその変化を検証した。
<筋ジストロフィーモデル犬を用いた筋ジストロフィー検出用マーカーの検証>
本発明の筋ジストロフィー検出用マーカー及びそれを用いた検出方法の効果を、筋ジストロフィーモデル犬を用いて検証した。mdxマウスは、ヒト筋ジストロフィー患者と異なり、歩行困難等の症状を示さないが、mdxマウスと同様にX染色体連鎖の劣性遺伝によりジストロフィン遺伝子を欠損する筋ジストロフィー犬は、歩行困難等のヒトと類似した症状を示す。したがって、よりヒトに近い効果を検証することができる。
筋ジストロフィーモデル犬としてX染色体上のジストロフィー遺伝子に異常を有するCXMDJ系統のビーグル犬、その保因犬(X染色体対の一方のジストロフィー遺伝子に異常を持つ雌ビーグル犬)及び健常犬(ジストロフィー遺伝子に異常のないビーグル犬)を用いた。
各犬の生後直後(0日)、1日後、2日後、2~4週後、2~3月後、6~7月後、12月後、24月後のそれぞれにおいて、29G注射針と0.5mLシリンジを用い、前肢又は後肢の皮静脈から100μL以上採血した。その後、実施例1と同様の方法により血清を調製し、一旦-80℃で冷凍保存した。実験には、各群から3~5標本ずつ、無作為に抽出して用いた。
結果を図4に示す。この図は、実施例1と同様に、リアルタイムPCRによるCXMDJ系統個体及び保因犬の血清中のmiR-1、miR-133a、miR-206及びクレアチンキナーゼのそれぞれの定量値をmiR-16の定量値によって補正し、その補正値を健常個体における対応する月齢の補正値に対する相対値として示したものである。
Claims (8)
- 被験体から採取された血液中に存在する配列番号1~4で示される塩基配列を含むmiRNAのいずれか一以上の量を測定する工程、
被験体の前記miRNAの血中量が健常個体の対応するmiRNAの血中量と比較して統計学的に有意に高いこととその被験体が筋原性疾患に罹患していることを関連づける工程
を含む被験体における筋原性疾患の罹患の有無を検出する方法。 - miRNAが配列番号1~4で示される塩基配列からなる、請求項1に記載の方法。
- 被験体の前記miRNAの血中量が健常個体における該miRNAの血中量の5倍以上である、請求項1又は2に記載の方法。
- miRNAの血中量を核酸増幅法又はハイブリダイゼーション法によって定量する、請求項1~3のいずれか一項に記載の方法。
- 核酸増幅法がリアルタイムPCR法である、請求項4に記載の方法。
- 前記血液が運動負荷後の被験体から採取されたものである、請求項1~5のいずれか一項に記載の方法。
- 前記筋原性疾患が筋ジストロフィーである、請求項1~6のいずれか一項に記載の方法。
- 配列番号1~4で示される塩基配列を含むmiRNAからなる筋原性疾患検出用マーカー。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011800087300A CN102753689A (zh) | 2010-02-26 | 2011-02-25 | 肌源性疾病检测用标记物及使用其的检测方法 |
US13/581,356 US20130034850A1 (en) | 2010-02-26 | 2011-02-25 | Marker for detecting myogenic disease and detection method using the same |
EP11747512.9A EP2540829B1 (en) | 2010-02-26 | 2011-02-25 | Marker for detection of myogenic diseases, and method for detection of the diseases using same |
JP2012501884A JP5748736B2 (ja) | 2010-02-26 | 2011-02-25 | 筋原性疾患検出用マーカー及びそれを用いた検出方法 |
US14/679,839 US20150211069A1 (en) | 2010-02-26 | 2015-04-06 | Marker for detecting myogenic disease and detection method using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010041845 | 2010-02-26 | ||
JP2010-041845 | 2010-02-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/581,356 A-371-Of-International US20130034850A1 (en) | 2010-02-26 | 2011-02-25 | Marker for detecting myogenic disease and detection method using the same |
US14/679,839 Division US20150211069A1 (en) | 2010-02-26 | 2015-04-06 | Marker for detecting myogenic disease and detection method using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011105556A1 true WO2011105556A1 (ja) | 2011-09-01 |
Family
ID=44506953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/054318 WO2011105556A1 (ja) | 2010-02-26 | 2011-02-25 | 筋原性疾患検出用マーカー及びそれを用いた検出方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20130034850A1 (ja) |
EP (1) | EP2540829B1 (ja) |
JP (1) | JP5748736B2 (ja) |
CN (1) | CN102753689A (ja) |
WO (1) | WO2011105556A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020534349A (ja) * | 2017-08-18 | 2020-11-26 | クラミス シーオー., エルティーディー.Curamys Co., Ltd. | 筋肉疾患および神経筋肉疾患の予防、治療または診断のためのmiR−18bの用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012279143A1 (en) * | 2011-07-01 | 2013-03-21 | Board Of Regents, The University Of Texas System | Compositions and methods for treating skeletal myopathy |
JPWO2017126479A1 (ja) * | 2016-01-22 | 2018-11-29 | アークレイ株式会社 | ターゲットの分析方法及びターゲット分析チップ |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11313682A (ja) * | 1998-04-30 | 1999-11-16 | Otsuka Pharmaceut Co Ltd | 福山型先天性筋ジストロフィー症原因蛋白質 |
JP2005304481A (ja) * | 2004-02-13 | 2005-11-04 | Joji Inasawa | ゲノムdnaの定着基盤と当該基盤を用いた染色体異常並びにそれに起因する疾患の検出方法 |
WO2009134710A2 (en) * | 2008-04-28 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Methods for enhancing utrophin production via inhibition of microrna |
JP2010041845A (ja) | 2008-08-06 | 2010-02-18 | Chugoku Electric Power Co Inc:The | 変圧器装柱具 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027818A (zh) * | 2005-12-12 | 2014-09-10 | 北卡罗来纳大学查珀尔希尔分校 | 调节肌细胞增殖和分化的microrna |
WO2007147409A2 (en) * | 2006-06-19 | 2007-12-27 | Københavns Universitet | Ribozyme mediated stabilization of polynucleotides |
US20100021914A1 (en) * | 2006-11-23 | 2010-01-28 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
US20110111976A1 (en) * | 2008-04-25 | 2011-05-12 | Merck Sharp & Dohme Corp. | Microrna biomarkers of tissue injury |
WO2009152111A1 (en) * | 2008-06-09 | 2009-12-17 | New York Medical College | Compositions comprising cardiac stem cells overexpressing specific micrornas and methods of their use in repairing damaged myocardium |
CN101386848A (zh) * | 2008-08-12 | 2009-03-18 | 南京大学 | 细胞微粒子所载微小核糖核酸及其制备研究方法和应用 |
EP2258863A1 (en) * | 2009-05-25 | 2010-12-08 | Universita'Degli Studi di Roma "La Sapienza" | miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics |
-
2011
- 2011-02-25 JP JP2012501884A patent/JP5748736B2/ja not_active Expired - Fee Related
- 2011-02-25 US US13/581,356 patent/US20130034850A1/en not_active Abandoned
- 2011-02-25 CN CN2011800087300A patent/CN102753689A/zh active Pending
- 2011-02-25 WO PCT/JP2011/054318 patent/WO2011105556A1/ja active Application Filing
- 2011-02-25 EP EP11747512.9A patent/EP2540829B1/en not_active Not-in-force
-
2015
- 2015-04-06 US US14/679,839 patent/US20150211069A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11313682A (ja) * | 1998-04-30 | 1999-11-16 | Otsuka Pharmaceut Co Ltd | 福山型先天性筋ジストロフィー症原因蛋白質 |
JP2005304481A (ja) * | 2004-02-13 | 2005-11-04 | Joji Inasawa | ゲノムdnaの定着基盤と当該基盤を用いた染色体異常並びにそれに起因する疾患の検出方法 |
WO2009134710A2 (en) * | 2008-04-28 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Methods for enhancing utrophin production via inhibition of microrna |
JP2010041845A (ja) | 2008-08-06 | 2010-02-18 | Chugoku Electric Power Co Inc:The | 変圧器装柱具 |
Non-Patent Citations (19)
Title |
---|
"DNA Microarray and Latest PCR Method", 2000, GAKKEN MEDICAL SHUJUNSHA CO., LTD. |
"Molecular Cloning: a Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Principle of Myology", 1995, NANKODO CO., LTD., pages: 469 - 550 |
"Toyosaka Moriizumi and Takamichi Nakamoto", 1997, SENSOR ENGINEERING, SHOKODO CO., LTD |
ARASHIRO P. ET AL: "Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers", PNAS, vol. 106, no. 15, April 2009 (2009-04-01), pages 6220 - 6225 * |
BARTEL DP, CELL, vol. 116, 2004, pages 281 - 297 |
CALLIS T.E. ET AL: "Muscling through the microRNA world", EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 233, no. 2, 2008, pages 131 - 138 * |
EISENBERG I. ET AL: "Distinctive patterns of microRNA expression in primary muscular disorders", PNAS, vol. 104, no. 43, October 2007 (2007-10-01), pages 17016 - 17021 * |
EISENBERG I. ET AL: "miRNAs in normal and diseased skeletal muscle", J. CELL. MOL. MED., vol. 13, no. 1, 2009, pages 2 - 11 * |
GRECO S. ET AL: "Common micro-RNA signature in skeletal muscle damage and regeneration induced by duchenne muscular dystrophy and acute ischemia", THE FASEB JOURNAL, vol. 23, October 2009 (2009-10-01), pages 3335 - 3346, XP002594658 * |
J. CHRISTOPHER LOVE; L.A. ESTROFF; J.K. KRIEBEL; R.G. NUZZO, G.M.: "Whitesides (2005) Self-Assembled Monolayers of a Form of Nanotechnology", CHEMICAL REVIEW, vol. 105, 2005, pages 1103 - 1169 |
KAZUHIRO NAGATA; HIROSHI HANDA: "Real-Time Analysis of Biomolecular Interactions", 2000, SPRINGER-VERLAG TOKYO, INC. |
KIM ET AL., J. CELL BIOCHEM, vol. 174, 2006, pages 677 - 687 |
KIM ET AL., J. CELL BIOCHEM., vol. 174, 2006, pages 677 - 687 |
MCCARTHY J.J. ET AL: "MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse", AM J PHYSIOL CELL PHYSIOL, vol. 293, 2007, pages C451 - C457 * |
NISHINO AND SANO: "Current Protocols in Molecular Biology", vol. I, 1997, MARUZEN CO., LTD |
SAMBROOK, J.: "Molecular Cloning: a Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP2540829A4 |
SUGITA H. ET AL., J. BIOCHEM., vol. 46, 1959, pages 103 - 104 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020534349A (ja) * | 2017-08-18 | 2020-11-26 | クラミス シーオー., エルティーディー.Curamys Co., Ltd. | 筋肉疾患および神経筋肉疾患の予防、治療または診断のためのmiR−18bの用途 |
US11286484B2 (en) | 2017-08-18 | 2022-03-29 | Curamys Co., Ltd. | Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease |
US11891604B2 (en) | 2017-08-18 | 2024-02-06 | Curamys Co., Ltd. | Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease |
Also Published As
Publication number | Publication date |
---|---|
EP2540829A1 (en) | 2013-01-02 |
EP2540829B1 (en) | 2015-11-25 |
JPWO2011105556A1 (ja) | 2013-06-20 |
EP2540829A4 (en) | 2013-07-17 |
JP5748736B2 (ja) | 2015-07-15 |
US20150211069A1 (en) | 2015-07-30 |
CN102753689A (zh) | 2012-10-24 |
US20130034850A1 (en) | 2013-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5520605B2 (ja) | 膵臓疾患で差次的に発現されるマイクロrnaおよびその使用 | |
DK2732052T3 (en) | Diagnostic microRNA profiling in cutaneous T cell lymphoma (CTCL) | |
US20100167948A1 (en) | MicroRNA Expression Profiling of Cerebrospinal Fluid | |
US8632967B2 (en) | Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent | |
US20120322680A1 (en) | Use of mirnas as biomarkers in glioma diagnosis | |
Bottani et al. | Perspectives on miRNAs as epigenetic markers in osteoporosis and bone fracture risk: a step forward in personalized diagnosis | |
WO2014075822A1 (en) | New diagnostic mirna markers for parkinson disease | |
US20190169690A1 (en) | Methods and compositions for diagnosis of alzheimer's disease | |
WO2014075911A1 (en) | Diagnostic mirna markers for alzheimer | |
US10655184B2 (en) | Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease | |
US20140342937A1 (en) | Methods for diagnosis and therapeutic follow-up of muscular dystrophies | |
US20190313957A1 (en) | Use of micro-ribonucleic acid (mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy | |
WO2016186987A1 (en) | Biomarker micrornas and method for determining tumor burden | |
EP3026121A1 (en) | Micro-RNA-based diagnosis of tuberculosis | |
JP5748736B2 (ja) | 筋原性疾患検出用マーカー及びそれを用いた検出方法 | |
CN107385037B (zh) | 一种miRNA间接实时荧光定量PCR检测方法 | |
EP3617326A1 (en) | Method for detecting minor bcr-abl1 gene | |
Pollet et al. | Host miRNAs as biomarkers of SARS-CoV-2 infection: a critical review | |
CN115418397B (zh) | 一种用于扩张型心肌病辅助诊断的生物标志物及其应用 | |
CN103757122B (zh) | 基于AllGlo探针荧光定量PCR的hsa-miR-188-5p检测试剂盒及其检测方法 | |
JP2017143810A (ja) | 抗酸菌症又は抗酸菌感染のバイオマーカー | |
CN102443638A (zh) | 一种用于血清/血浆miRNA检测的内参及其应用 | |
Lv et al. | MicroRNA expression profiling in Guillain-Barre syndrome | |
TWI704927B (zh) | 乾癬性關節炎的診斷及治療、與其之套組 | |
Chen et al. | Single-molecule assay guided crRNA optimization enhances specific microRNA detection by CRISPR-Cas12a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180008730.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11747512 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012501884 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13581356 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011747512 Country of ref document: EP |